(Q38445978)

3 September 2017

title

Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis (English)

1 reference

3 September 2017

0 references

1 reference

Hermann Brustmann

1

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

3 September 2017

1 reference

3 September 2017

volume

95

1 reference

3 September 2017

issue

1

1 reference

3 September 2017

page(s)

16-22

1 reference

The biology of vascular endothelial growth factor

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

DNA topoisomerase IIalpha and -beta expression in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.07.040

10.1016/J.YGYNO.2004.07.040

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference